![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Illustrative of the emerging complexity of cancer and its therapy is the case of Endothelin-1 (ET-1) in prostate cancer. Despite pre-clinical data suggesting that ET-1 might play a role in cancer progression and/or metastasis, clinical trials using ET-1 antagonists have yielded mixed results. In the current issue of Cancer Biology and Therapy, Weydert and colleagues attempt to understand what other effects ET-1 may be having during tumorigenesis. By overexpressing ET-1 in two prostate cancer cell lines, they assess the ability of ET-1 to promote tumor progression and metastasis. Despite tissue culture results demonstrating that overexpression of ET-1 can promote the growth of prostate cancer cells, xenografts using these cells failed to grow. On the cover is a 3D image reconstruction of tumor-feeding arterioles. Following whole-mouse MICROFIL silicone rubber perfusion, micro-computed tomography analysis of these radio-opaque vascular casts reveals vessels within subcutaneous PC-3 tumors. To see how over expression of ET-1 affects the vessels in subcutaneous tumors, see the article by Weydert et al.